Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial

[11] Scheiman J(2006)Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM study Am J Gastroenterol 101 1747-1755

[12] Abraham NS(2011)Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole vs. omeprazole J Gastroenterol 46 724-735

[13] Antman EM(1981)Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial Am J Gastroenterol 75 17-21

[14] Chan FK(2005)A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa Aliment Pharmacol Ther 21 1055-1061

[15] Furberg CD(1991)Systematic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia—a post hoc analysis from the Cochrane Collaboration Ann Intern Med 115 195-200

[16] Hawkey CJ(1997)Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial Bioimaging 5 134-138

[17] Karrasch JA(1998)Fluorescence correlation spectroscopy as a detection tool of point mutation in gene Dig Dis Sci 43 2764-2770

[18] Szczepañski L(1998)Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-α, bFGF, and EGF receptor expression in humans Am J Gastroenterol 93 1271-1276

[19] Walker DG(2010) infection and gastric neoplasia: correlations with histological gastritis and tumor histology Helicobacter 15 1-20

[20] Barkun A(2008)Guidelines for the management of Lancet 372 392-397

[11] Scheiman J(2006)Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM study Am J Gastroenterol 101 1747-1755

[12] Abraham NS(2011)Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole vs. omeprazole J Gastroenterol 46 724-735

[13] Antman EM(1981)Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial Am J Gastroenterol 75 17-21

[14] Chan FK(2005)A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa Aliment Pharmacol Ther 21 1055-1061

[15] Furberg CD(1991)Systematic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia—a post hoc analysis from the Cochrane Collaboration Ann Intern Med 115 195-200

[16] Hawkey CJ(1997)Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial Bioimaging 5 134-138

[17] Karrasch JA(1998)Fluorescence correlation spectroscopy as a detection tool of point mutation in gene Dig Dis Sci 43 2764-2770

[18] Szczepañski L(1998)Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-α, bFGF, and EGF receptor expression in humans Am J Gastroenterol 93 1271-1276

[19] Walker DG(2010) infection and gastric neoplasia: correlations with histological gastritis and tumor histology Helicobacter 15 1-20

[20] Barkun A(2008)Guidelines for the management of Lancet 372 392-397